Inclusion Criteria:

- histologically or cytologically confirmed invasive thymoma or thymic carcinoma

- unresectable tumor: by either local invasion, distant metastasis, or recurred
(assessed by investigator)

- no previous systemic treatment for invasive thymoma or thymic carcinoma

- at least one measurable lesion by RECIST criteria

- 18 years old or older

- ECOG performance status 0, 1, 2

- adequate lab. findings neutrophil ≥ 1.5 x 10^9/L platelet ≥ 75 x 10^9/L hemoglobin ≥
9.0 g/dL bilirubin ≤ 1.5 x upper normal limit AST, ALT ≤ 2.5 x upper normal limit
Alkaline phosphatase ≤ 2.5 x upper normal limit (if liver metastasis, ≤ 5 x upper
normal limit) serum creatinine ≤ 1.0 x upper normal limit if serum creatinine > 1.0 x
upper normal limit, creatinine clearance ≥ 60 mL/min

- patient who agree to written, informed consent

Exclusion Criteria:

- other malignancy (exception: non-melanoma skin cancer, cervical carcinoma in situ,
cancer without evidence more than 5 years since curative resection)

- active bacterial infection

- history of clinical trial with investigational drug within 30 days

- radiotherapy to thoracic or mediastinal area (other area radiotherapy is permitted)

- pregnant, or lactating women

- patient with organ transplantation

- peripheral neuropathy, grade 2 or greater

- severe, medical condition unstable cardiac disease despite of adequate management
myocardial infarction within 6 months active ulcer disease refractory to medication
chronic obstructive lung disease requiring admission treatment within 1 year

- uncontrolled seizure, cerebral nervous system disorder, psychiatric problem which
decrease treatment compliance